Literature DB >> 28507173

Resistant Hypertension: An Update of Experimental and Clinical Findings.

Anping Cai1, David A Calhoun2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28507173      PMCID： PMC5515281          DOI： 10.1161/HYPERTENSIONAHA.117.08929

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  39 in total

1.  Eligibility for renal denervation: experience at 11 European expert centers.

Authors:  Alexandre Persu; Yu Jin; Marie Baelen; Eva Vink; Willemien L Verloop; Bernhard Schmidt; Marie K Blicher; Francesca Severino; Grégoire Wuerzner; Alison Taylor; Antoinette Pechère-Bertschi; Fadi Jokhaji; Fadl Elmula M Fadl Elmula; Jan Rosa; Danuta Czarnecka; Georg Ehret; Thomas Kahan; Jean Renkin; Jiři Widimsky; Lotte Jacobs; Wilko Spiering; Michel Burnier; Patrick B Mark; Jan Menne; Michael H Olsen; Peter J Blankestijn; Sverre Kjeldsen; Michiel L Bots; Jan A Staessen
Journal:  Hypertension       Date:  2014-03-24       Impact factor: 10.190

2.  Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension.

Authors:  Steffen Desch; Thomas Okon; Diana Heinemann; Konrad Kulle; Karoline Röhnert; Melanie Sonnabend; Martin Petzold; Ulrike Müller; Gerhard Schuler; Ingo Eitel; Holger Thiele; Philipp Lurz
Journal:  Hypertension       Date:  2015-03-30       Impact factor: 10.190

3.  Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.

Authors:  George Thomas; Dawei Xie; Hsiang-Yu Chen; Amanda H Anderson; Lawrence J Appel; Shirisha Bodana; Carolyn S Brecklin; Paul Drawz; John M Flack; Edgar R Miller; Susan P Steigerwalt; Raymond R Townsend; Matthew R Weir; Jackson T Wright; Mahboob Rahman
Journal:  Hypertension       Date:  2015-12-28       Impact factor: 10.190

4.  Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study.

Authors:  Ján Rosa; Petr Widimský; Petr Waldauf; Lukáš Lambert; Tomáš Zelinka; Miloš Táborský; Marian Branny; Petr Toušek; Ondřej Petrák; Karol Čurila; František Bednář; Robert Holaj; Branislav Štrauch; Jan Václavík; Igor Nykl; Zuzana Krátká; Eva Kociánová; Otakar Jiravský; Gabriela Rappová; Tomáš Indra; Jiří Widimský
Journal:  Hypertension       Date:  2015-12-22       Impact factor: 10.190

5.  Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.

Authors:  Esther de Beus; Michiel L Bots; Arjan D van Zuilen; Jack F M Wetzels; Peter J Blankestijn
Journal:  Hypertension       Date:  2015-09-08       Impact factor: 10.190

6.  Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014.

Authors:  Andrew Y Hwang; Chintan Dave; Steven M Smith
Journal:  Hypertension       Date:  2016-10-24       Impact factor: 10.190

7.  Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system.

Authors:  Vasilios Papademetriou; Costas P Tsioufis; Ajay Sinhal; Derek P Chew; Ian T Meredith; Yuvi Malaiapan; Matthew I Worthley; Stephen G Worthley
Journal:  Hypertension       Date:  2014-06-16       Impact factor: 10.190

8.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321
View more
  15 in total

Review 1.  Recent Advances in Neurogenic Hypertension: Dietary Salt, Obesity, and Inflammation.

Authors:  Sean D Stocker; Brian J Kinsman; Alan F Sved
Journal:  Hypertension       Date:  2017-07-24       Impact factor: 10.190

2.  Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP.

Authors:  Yang Chen; Jacob J Schaefer; Seethalakshmi R Iyer; Gerald E Harders; Shuchong Pan; S Jeson Sangaralingham; Horng H Chen; Margaret M Redfield; John C Burnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-02-05       Impact factor: 3.619

Review 3.  Sympathetic Nervous System Contributions to Hypertension: Updates and Therapeutic Relevance.

Authors:  Leon J DeLalio; Alan F Sved; Sean D Stocker
Journal:  Can J Cardiol       Date:  2020-03-06       Impact factor: 5.223

4.  Brazilian Position Statement on Resistant Hypertension - 2020.

Authors:  Juan Carlos Yugar-Toledo; Heitor Moreno Júnior; Miguel Gus; Guido Bernardo Aranha Rosito; Luiz César Nazário Scala; Elizabeth Silaid Muxfeldt; Alexandre Alessi; Andrea Araújo Brandão; Osni Moreira Filho; Audes Diógenes de Magalhães Feitosa; Oswaldo Passarelli Júnior; Dilma do Socorro Moraes de Souza; Celso Amodeo; Weimar Kunz Sebba Barroso; Marco Antônio Mota Gomes; Annelise Machado Gomes de Paiva; Eduardo Costa Duarte Barbosa; Roberto Dischinger Miranda; José Fernando Vilela-Martin; Wilson Nadruz Júnior; Cibele Isaac Saad Rodrigues; Luciano Ferreira Drager; Luiz Aparecido Bortolotto; Fernanda Marciano Consolim-Colombo; Márcio Gonçalves de Sousa; Flávio Antonio de Oliveira Borelli; Sérgio Emanuel Kaiser; Gil Fernando Salles; Maria de Fátima de Azevedo; Lucélia Batista Neves Cunha Magalhães; Rui Manoel Dos Santos Póvoa; Marcus Vinícius Bolívar Malachias; Armando da Rocha Nogueira; Paulo César Brandão Veiga Jardim; Thiago de Souza Veiga Jardim
Journal:  Arq Bras Cardiol       Date:  2020 May-Jun       Impact factor: 2.000

Review 5.  Immune mechanisms of hypertension.

Authors:  Grant R Drummond; Antony Vinh; Tomasz J Guzik; Christopher G Sobey
Journal:  Nat Rev Immunol       Date:  2019-08       Impact factor: 53.106

6.  Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Michael Doumas
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-12-13       Impact factor: 3.738

7.  Single-cell RNA sequencing reveals cell type- and artery type-specific vascular remodelling in male spontaneously hypertensive rats.

Authors:  Jun Cheng; Wenduo Gu; Ting Lan; Jiacheng Deng; Zhichao Ni; Zhongyi Zhang; Yanhua Hu; Xiaolei Sun; Yan Yang; Qingbo Xu
Journal:  Cardiovasc Res       Date:  2021-03-21       Impact factor: 10.787

8.  Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis.

Authors:  Giovanna Bacan; Angélica Ribeiro-Silva; Vinicius A S Oliveira; Claudia R L Cardoso; Gil F Salles
Journal:  Curr Hypertens Rep       Date:  2022-02-02       Impact factor: 5.369

9.  Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.

Authors:  Elizabeth do Espirito Santo Cestário; Letícia Aparecida Barufi Fernandes; Luiz Tadeu Giollo-Júnior; Jéssica Rodrigues Roma Uyemura; Camila Suemi Sato Matarucco; Manoel Idelfonso Paz Landim; Luciana Neves Cosenso-Martin; Lúcia Helena Bonalume Tácito; Heitor Moreno; José Fernando Vilela-Martin; Juan Carlos Yugar-Toledo
Journal:  Trials       Date:  2018-02-12       Impact factor: 2.279

10.  Importance of the renal ion channel TRPM6 in the circadian secretion of renin to raise blood pressure.

Authors:  Yosuke Funato; Daisuke Yamazaki; Daisuke Okuzaki; Nobuhiko Yamamoto; Hiroaki Miki
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.